NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

CytoMed Therapeutics Limited (GDTC) Stock Analysis

CytoMed Therapeutics Limited (GDTC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GDTC

$0.92

+$0.05 (+5.45%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GDTC with… →

GDTC Key Statistics

As of Oct 21, 2026
Trading
Open
$0.81
Previous Close
$0.87
Day's Range
0.81–0.92
52-Week Range
0.68–3.68
Volume
4.99K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.07
Valuation
Market Cap
$10.97M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.90
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.23
Financials (FY)
Revenue (FY)
$324.39K+366.74%
Net Income (FY)
−$3.98M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
11.93M
1-Year Return
−64.24%
Dividend and dates
Avg Volume
79.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GDTC closed at $0.92, −64.24% over 1 year.

CytoMed Therapeutics Limited (GDTC) has a market capitalization of $10.97M.

In fiscal 2025, GDTC reported revenue of $324.39K.

GDTC Stock Return by Calendar Year

CytoMed Therapeutics Limited (GDTC) return since Apr 2023: what $10,000 became

1 year
$10,000 $3,576
−64.24%
3 years
$10,000 $2,560
−74.40%
Since Apr 2023
$10,000 $2,297
−77.03%

If you had invested $10,000 in CytoMed Therapeutics Limited (GDTC) at the close on April 14, 2023, the earliest close on record here, it would have been worth $2,297 at the close on October 21, 2026: −77.03% in total, −34.15% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−31.16%
2025−60.74%
2024−30.61%
2023 (partial year)+22.50%

As of October 21, 2026.

GDTC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$324.39K−$3.98M−1,227.1%
2024$69.50K−$2.52M−3,621.1%
2023$0.00−$4.13M—
2022$0.00−$3.13M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$324.39K$256.40K−$4.24M−$3.98M−1,227.1%
2024$69.50K$52.38K−$3.13M−$2.52M−3,621.1%
2023$0.00$0.00−$3.84M−$4.13M—
2022$0.00$0.00−$1.86M−$3.13M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GDTC Valuation vs Biotechnology Median

Median of 608 stocks
MetricGDTCBiotechnology medianvs median
P/S ratio13.9013.305% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values CytoMed Therapeutics Limited (GDTC) at $10.97M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 42.

GDTC last closed at $0.92 on October 21, 2026. That is +$0.05 (+5.45%) against the previous close. The 52-week range on file runs from $0.68 to $3.68. The latest close sits 35.15% above that 52-week low.

Financial Health

In fiscal 2025, CytoMed Therapeutics Limited reported revenue of $324.39K. That is +366.74% against the prior fiscal year, when revenue was $69.50K. The same year closed with a net loss of $3.98M. Trailing earnings per share are −0.23.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $324.39K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 13.9. On price-to-sales that is 4.53% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −64.24%. Across 3 years the annualized return works out at −36.50%. Beta against the wider market is reported at 0.07. Daily returns over the trailing 3 years annualize to a volatility of 88.57%.

Growth & Income

No dividend is on file for GDTC.

2026 is still running; the total return is −31.16% year to date. The strongest complete calendar year on file is 2024 at −30.61%; the weakest is 2025 at −60.74%.

Peer Comparison

CytoMed Therapeutics Limited (GDTC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CytoMed Therapeutics Limited GDTC $10.97M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. CytoMed Therapeutics Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About CytoMed Therapeutics Limited

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Visit website →